Clinical Trials Browser

Carcinoma × dacomitinib × Clear all

NCT00728390 2024-04-22

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

Phase 1 Completed

Carcinoma, Neoplasm Metastasis

NCT00818441 2019-01-08

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Phase 2 Completed

119 enrolled 12 charts

Carcinoma